Two 12-week phase 3 trials and a 43-week extension will test 8 mg and 16 mg HLP003 added to antidepressants, with APPROACH enrollment now complete.
|Articles|September 16, 2008
- October15 2004
- Volume 11
- Issue 19
Pharmaceutical Stock Watch
Advertisement
Articles in this issue
about 18 years ago
Question Your Ideal Investment Optionabout 18 years ago
Determine when a Roth IRA Makes Senseabout 18 years ago
Ponder the Privatized Social Security Issueabout 18 years ago
Accelerate Retirement Savings with a 412(i)about 18 years ago
Replace Malpractice Fiction with Factabout 18 years ago
Expand Your Insurance Protection Planabout 18 years ago
Save More with College Rewards Programsabout 18 years ago
Select a Team Worthy of the Super Bowlabout 18 years ago
Recover Taxes from a Natural Disasterabout 18 years ago
Strengthen Your Retirement with CharityAdvertisement
Related to this article
This preview of EADV 2026 provides a teaser of new data and interviews being highlighted at this Vienna dermatology conference.
Phase 2b AMPLIFIED data show a 42.7% UACR drop in AMKD with modest proteinuria; AMPLITUDE interim data are due early 2027.
George Vasquez-Rios, MD, explains how the ASN's GD-C Compendium curates glomerular disease guidance for general clinicians and specialists alike.
Andrew Cutler, MD, says real-world MDD patients respond to adjunctive cariprazine like trial participants, with gains in mood and function within weeks.
Frances Lee, MD, on the stigma driving under-detection of ALD and its disproportionate rise in women and younger adults.
SOCS leaders explain SOCS Serves, a toolkit-based program connecting dermatology volunteers with students and underserved communities.
EMBARQ-CSU1 and EMBARQ-CSU2 showed sustained reductions in urticaria, with the antibody meeting all primary and key secondary endpoints at Week 12.
Advertisement
Advertisement
Trending on HCPLive
1
Half-Life vs. Real Life: How Real-World Evidence Is Reframing Wet AMD Treatment
2
ProACt Data Show Early Functional Gains with Adjunctive Cariprazine In MDD
3
FDA Updates Sotatercept Label with HYPERION Data in Early PAH
4
EMBARQ-CSU: Barzolvolimab Meets Primary, Secondary Endpoints in CSU Trials
5